https://www.selleckchem.com/products/yd23.html
Objective Accurate evaluation of tumor programmed death ligand 1 (PD-L1) expression can assist in predicting whether a patient will respond to anti-PD-L1 therapy. In this study, we aimed to develop stable radioiodinated PD-L1 antibodies that can be used for PD-L1 targeted SPECT/PET imaging. Methods Radioiodination was accomplished via a prosthetic group ([131I]SIB or [124I]SI to give radioiodinated anti-human PD-L1 and anti-mouse PD-L1 antibody (anti-PD-L1 and anti-PD-L1M). MicroSPECT/PET imaging and biodistribution of radioiodinated ant
Like
Comment
Share
